发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010. 大麻素受体2型配体:2010年以来授权专利分析。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-05-01 Epub Date: 2021-06-11 DOI: 10.4155/ppa-2021-0002
Benjamin Brennecke, Thais Gazzi, Kenneth Atz, Jürgen Fingerle, Pascal Kuner, Torsten Schindler, Guy de Weck, Marc Nazaré, Uwe Grether
{"title":"Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010.","authors":"Benjamin Brennecke,&nbsp;Thais Gazzi,&nbsp;Kenneth Atz,&nbsp;Jürgen Fingerle,&nbsp;Pascal Kuner,&nbsp;Torsten Schindler,&nbsp;Guy de Weck,&nbsp;Marc Nazaré,&nbsp;Uwe Grether","doi":"10.4155/ppa-2021-0002","DOIUrl":"https://doi.org/10.4155/ppa-2021-0002","url":null,"abstract":"<p><p>The G-protein-coupled cannabinoid receptor type 2 (CB<sub>2</sub>R) is a key element of the endocannabinoid (EC) system. EC/CB<sub>2</sub>R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative disorders, inflammation or ocular diseases. CB<sub>2</sub>R agonism exerts anti-inflammatory and tissue protective effects in preclinical animal models of cardiovascular, gastrointestinal, liver, kidney, lung and neurodegenerative disorders. Existing ligands can be subdivided into endocannabinoids, cannabinoid-like and synthetic CB<sub>2</sub>R ligands that possess various degrees of potency on and selectivity against the cannabinoid receptor type 1. This review is an account of granted CB<sub>2</sub>R ligand patents from 2010 up to the present, which were surveyed using Derwent Innovation<sup>®</sup>.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 3","pages":"111-163"},"PeriodicalIF":1.3,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39081313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Recent development of drugs for osteoporosis and anti-cancer agents: a patent analysis. 骨质疏松和抗癌药物的最新进展:专利分析。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-03-01 Epub Date: 2021-04-12 DOI: 10.4155/ppa-2021-0004
Hai-Long Zhang, Yiqian Li
{"title":"Recent development of drugs for osteoporosis and anti-cancer agents: a patent analysis.","authors":"Hai-Long Zhang,&nbsp;Yiqian Li","doi":"10.4155/ppa-2021-0004","DOIUrl":"https://doi.org/10.4155/ppa-2021-0004","url":null,"abstract":"<p><p>Osteoporosis and cancer are becoming a major public health problem. Some studies have shown that osteoporosis drugs may have anti-cancer effects. To better understand the relationship between drugs for osteoporosis and antineoplastic agents, and to better demonstrate recent developments for patents concerning drugs for osteoporosis, we conducted an analysis of US patents. The results indicated that there was a good correlation between agents for osteoporosis and antineoplastic agents, which indicated that numerous anti-osteoporosis agents displayed antineoplastic activities. Our study was the first one to provide new evidence, through comprehensive analysis, for a correlation between anti-osteoporosis agents and anticancer agents. The present study may open new avenues for developing anticancer drugs and expanding the application role of anti-osteoporosis agents.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 2","pages":"73-82"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25581887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Patent highlights October-November 2020. 专利要点 2020 年 10 月至 11 月。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2021-03-01 Epub Date: 2021-02-17 DOI: 10.4155/ppa-2021-0003
Hermann Am Mucke
{"title":"Patent highlights October-November 2020.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2021-0003","DOIUrl":"10.4155/ppa-2021-0003","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 2","pages":"51-58"},"PeriodicalIF":1.8,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25375469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bispecific anti-OX40/5T4 antibodies for cancer treatment. 用于癌症治疗的双特异性抗ox40 / 5t4抗体。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-03-01 Epub Date: 2021-03-12 DOI: 10.4155/ppa-2020-0030
Martin Perez-Santos
{"title":"Bispecific anti-OX40/5T4 antibodies for cancer treatment.","authors":"Martin Perez-Santos","doi":"10.4155/ppa-2020-0030","DOIUrl":"https://doi.org/10.4155/ppa-2020-0030","url":null,"abstract":"<p><p>OX40 and 5T4 are molecules that play a role in T-cell expansion and cytoskeleton's disruption in cancer, respectively. US2019161555 patent describes a bispecific antibody that targets OX40/5T4 with the potential application of cancer treatment. The method of analysis of the US201916155 patent consisted of claim's analysis, as well as the chemical/biological information's analysis of the bispecific antibody. The patent includes independent claims related to bispecific antibodies that bind to OX40/5T4, DNA encoding the antibodies, a vector that harbors the DNA, a host cell that contains the vector, a pharmaceutical composition containing a pharmaceutically effective amount of the antibodies, medical use of the antibodies, use of the antibodies in the treatment or prevention of neoplastic disorders and a method of treating neoplastic disorders. Bispecific antibodies that target OX40/5T4 can activate IL-2 secretion in CD4<sup>+</sup> T cells.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 2","pages":"59-66"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25468368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody. 双特异性抗pdl -1/ICOS抗体治疗实体瘤。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-03-01 Epub Date: 2021-04-08 DOI: 10.4155/ppa-2020-0035
Martin Perez-Santos, Maricruz Anaya-Ruiz, Gabriela Sanchez-Esgua, Luis Villafaña-Diaz, Diana Barron-Villaverde
{"title":"Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody.","authors":"Martin Perez-Santos,&nbsp;Maricruz Anaya-Ruiz,&nbsp;Gabriela Sanchez-Esgua,&nbsp;Luis Villafaña-Diaz,&nbsp;Diana Barron-Villaverde","doi":"10.4155/ppa-2020-0035","DOIUrl":"https://doi.org/10.4155/ppa-2020-0035","url":null,"abstract":"<p><p>PD-L1 and ICOS are immune control points in cancer and their presence in cancer tends to have a poor prognosis. WO2019122882 patent describes a bispecific antibody that targets PDL-1/ICOS with the potential application of cancer treatment. WO2019122882 patent describes a bispecific antibody with antitumor efficacy in CT26 model through of the depletion of T<sub>Reg</sub> cells and improved ratio of CD8<sup>+</sup> T cells: T<sub>Reg</sub> in tumor microenvironment. The anti-PDL-1/ICOS antibody is new; however, only preclinical assays are shown using colon carcinoma model. So far, there are no reports of clinical trials to evaluate the safety, toxicity and efficacy, but it will be of great interest to analyze in the future if this antibody surpasses the action of the combinatorial therapy in cancer.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 2","pages":"67-72"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25586617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vaccines against antimicrobial resistance: a promising escape route for multidrug resistance. 抗微生物药物耐药性疫苗:一种有希望的多药耐药性逃避途径。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-03-01 Epub Date: 2021-04-08 DOI: 10.4155/ppa-2020-0022
Absar Talat, Asad U Khan
{"title":"Vaccines against antimicrobial resistance: a promising escape route for multidrug resistance.","authors":"Absar Talat,&nbsp;Asad U Khan","doi":"10.4155/ppa-2020-0022","DOIUrl":"https://doi.org/10.4155/ppa-2020-0022","url":null,"abstract":"<p><p>Antibiotic resistance has become a global health problem requiring urgent intervention. The pace of development and frequency of transmission of antimicrobial resistance have tremendously surpassed the number of antibiotics developed in the past few decades. Emergence and transmission of multidrug-resistant genes, for example, <i>mcr-1</i> and <i>mcr-5.3</i>, against the last resort of antibiotics has challenged the treatment options. Vaccination is a promising approach with no instance of antimicrobial resistance generation or transmission reported so far. The time required for developing a vaccine, extensive pre- and post-licensure studies and the financial constraints for the R&D has hampered vaccine development over the past few decades. Vaccine can prove to be an effective future strategy for combating antimicrobial resistance.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 2","pages":"83-98"},"PeriodicalIF":1.3,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25570550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Protein-based nanoplatform for detection of tumorigenic polyps in the colon via noninvasive mucosal routes. 基于蛋白质的纳米平台，可通过非侵入性粘膜途径检测结肠中的肿瘤性息肉。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-01-20 DOI: 10.4155/ppa-2020-0034
Chun-Chieh Chen, Mo A Baikoghli, R Holland Cheng
{"title":"Protein-based nanoplatform for detection of tumorigenic polyps in the colon via noninvasive mucosal routes.","authors":"Chun-Chieh Chen, Mo A Baikoghli, R Holland Cheng","doi":"10.4155/ppa-2020-0034","DOIUrl":"10.4155/ppa-2020-0034","url":null,"abstract":"<p><p>The use of nanoparticulate systems to diagnose and treat tumors has gained momentum with the rapid development of nanomedicine. Many nanotheranostics fail due to insufficient bioavailability and low accumulation at the tumor site, resulting in undesirable side effects. We describe the use of an engineered hepatitis E viral nanoparticle (HEVNP) with enhanced bioavailability, tissue retention and mucosal penetration capacities. HEVNP is a modular nanocapsule that can encapsulate heterologous nucleotides, proteins and inorganic metals, such as ferrite oxide nanoparticles. Additionally, the exterior protruding arms of HEVNP is composed of loops that are used for chemical coupling of targeting and therapeutic peptides. We propose the use of HEVNP to target colorectal cancer (i.e., polyps) with imaging-guided delivery using colonoscopy.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2021-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818166/pdf/ppa-10-13.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38836915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights August-September 2020. 专利要点 2020 年 8 月至 9 月。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2021-01-01 Epub Date: 2021-01-14 DOI: 10.4155/ppa-2020-0032
Hermann Am Mucke
{"title":"Patent highlights August-September 2020.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2020-0032","DOIUrl":"10.4155/ppa-2020-0032","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 1","pages":"1-7"},"PeriodicalIF":1.8,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38815855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent patents on therapeutic activities of xanthohumol: a prenylated chalconoid from hops (Humulus lupulus L.). 黄腐酚:一种从啤酒花(Humulus lupulus L.)中提取的烯基化chalconoid。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-01-01 Epub Date: 2021-01-15 DOI: 10.4155/ppa-2020-0026
Diwakar Aggarwal, Sushil K Upadhyay, Raj Singh, Hardeep S Tuli
{"title":"Recent patents on therapeutic activities of xanthohumol: a prenylated chalconoid from hops (<i>Humulus lupulus</i> L.).","authors":"Diwakar Aggarwal,&nbsp;Sushil K Upadhyay,&nbsp;Raj Singh,&nbsp;Hardeep S Tuli","doi":"10.4155/ppa-2020-0026","DOIUrl":"https://doi.org/10.4155/ppa-2020-0026","url":null,"abstract":"<p><p>There is expanding proof that specific natural compounds found in plants have additional conventional medicinal properties. One such compound is xanthohumol (XN), which is being explored as an antimicrobial, anticarcinogenic, antidiabetic and anti-inflammatory agent - aside from its utilization in dealing with conditions like autism, bone and skin improvement and microbial infections, lipid-related illnesses, and so on. XN is reported to suppress the uncontrolled production of inflammatory mediators responsible for diseases including cardiovascular disease, neurodegeneration and tumors. Further, it is accounted to limit adipogenesis and control obesity by focusing on principal adipocyte marker proteins. It is most generally utilized in the brewing industry as an additive and flavoring agent to add bitterness and aroma to beer. Present investigation sum up the patents filed in most recent 2 years on development of different pharmaceutical mixes and strategies dependent on various therapeutic potentials of XN.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 1","pages":"37-49"},"PeriodicalIF":1.3,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38740706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Mnk inhibitors: a patent review. 锰酸盐抑制剂:专利审查。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2021-01-01 Epub Date: 2021-01-14 DOI: 10.4155/ppa-2020-0028
Ahmed M Abdelaziz, Mingfeng Yu, Shudong Wang
{"title":"Mnk inhibitors: a patent review.","authors":"Ahmed M Abdelaziz,&nbsp;Mingfeng Yu,&nbsp;Shudong Wang","doi":"10.4155/ppa-2020-0028","DOIUrl":"https://doi.org/10.4155/ppa-2020-0028","url":null,"abstract":"<p><p>The alteration of mRNA translation has a crucial role in defining the changes in cellular proteome. The phosphorylation of eukaryotic initiation factor 4E by mitogen-activated protein kinase-interacting kinases (Mnks) leads to the release and translation of mRNAs of specific oncogenic proteins. In recent years, the efforts made by the pharmaceutical industry to develop novel chemical skeletons to create potent and selective Mnk inhibitors have been fruitful. The pyridone-aminal scaffold has been utilized to generate several series of Mnk inhibitors presented in multiple patent applications and research articles. Tomivosertib (eFT508) is one of the molecules with such scaffold. It is one of the first two Mnk inhibitors that entered clinical trials, and has displayed momentous activity against several solid and hematological cancers. The present compilation provides a succinct review of the current state of development of pyridone-aminal-derived Mnk inhibitors through the analysis of relevant patent applications filed in the last 5 years.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":"10 1","pages":"25-35"},"PeriodicalIF":1.3,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38749867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信